Oncolytics Biotech (TSE:ONC) Shares Pass Below 200-Day Moving Average – Here’s Why

Oncolytics Biotech Inc. (TSE:ONCGet Free Report) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of C$1.39 and traded as low as C$1.18. Oncolytics Biotech shares last traded at C$1.21, with a volume of 144,265 shares trading hands.

Analysts Set New Price Targets

Separately, Raymond James upgraded shares of Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.

Get Our Latest Report on ONC

Oncolytics Biotech Stock Down 3.2 %

The stock has a market capitalization of C$93.00 million, a P/E ratio of -3.18 and a beta of 1.35. The stock has a 50 day moving average price of C$1.33 and a 200-day moving average price of C$1.39. The company has a debt-to-equity ratio of 6.09, a current ratio of 4.99 and a quick ratio of 8.86.

Oncolytics Biotech Company Profile

(Get Free Report)

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.

Recommended Stories

Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.